FDA — authorised 12 April 2010
- Application: BLA022523
- Marketing authorisation holder: VIVUS INC
- Indication: Type 7 - Drug Already Marketed without Approved NDA
- Status: approved
FDA authorised CREON on 12 April 2010
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 12 April 2010; FDA authorised it on 20 March 2020.
VIVUS INC holds the US marketing authorisation.